DNA-protein biomarkers for immunotherapy in the era of precision oncology

키워드

참고문헌 (47)

1. Hoadley KA, "Cell-of-origin patterns dominate the molecular classification of 10, 000 tumors from 33 types of cancer", Cell, 173, pp.291~304 (2018)
2. Hyman DM, "Implementing genome-driven oncology", Cell, 168, pp.584~599 (2017)
3. Duffy MJ, "Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients", Clin Chem, 65, pp.1228~1238 (2019)
4. Stenzinger A, "Tumor mutational burden standardization initiatives : Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions", Genes Chromosomes Cancer, 58, pp.578~588 (2019)
5. Chalmers ZR, "Analysis of 100, 000human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
6. Kim J, "Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer", Front Oncol, 10, pp.314~ (2020)
7. Samstein RM, "Tumor mutational load predicts survival after immunotherapy across multiple cancer types", Nat Genet, 51, pp.202~206 (2019)
8. Cho J, "Bridging genomics and phenomics of gastric carcinoma", Int J Cancer, 145, pp.2407~2417 (2019)
9. Goodman AM, "Tumor mutational burden as an independent predictor of response to immunotherapy in dverse cancers", Mol Cancer Ther, 16, pp.2598~2608 (2017)
10. Vanderwalde A, "Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11, 348 patients", Cancer Med, 7, pp.746~756 (2018)
11. Ricciuti B, "Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer", J Immunother Cancer, 7, pp.87~ (2019)
12. Fabrizio DA, "Beyond microsatellite testing : assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition", J Gastrointest Oncol, 9, pp.610~617 (2018)
13. Hellmann MD, "Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden", N Engl J Med, 378, pp.2093~2104 (2018)
14. Ready N, "First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer(Check-Mate 568) : outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers", J Clin Oncol, 37, pp.992~1000 (2019)
15. Rosenberg JE, "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy : a single-arm, multicentre, phase 2 trial", Lancet, 387, pp.1909~1920 (2016)
16. Powles T, "Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma(IMvigor211) : a multicentre, open-label, phase 3 randomised controlled trial", Lancet, 391, pp.748~757 (2018)
17. Weinberg BA, "Immuno-oncology biomarkers for gastric and gastroesophageal junction adenocarcinoma : why PD-L1 testing may not be enough", Oncologist, 23, pp.1171~1177 (2018)
18. Mishima S, "Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer", J Immunother Cancer, 7, pp.24~ (2019)
19. Melendez B, "Methods of measurement for tumor mutational burden in tumor tissue", Transl Lung Cancer Res, 7, pp.661~667 (2018)
20. Kim S, "Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine", J Mol Diagn, 19, pp.137~146 (2017)
21. Garofalo A, "The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine", Genome Med, 8, pp.79~ (2016)
22. Cho J, "Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability", ESMO Open, 3, pp.e000326~ (2018)
23. Ionov Y, "Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis", Nature, 363, pp.558~561 (1993)
24. Peltomaki P, "Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome", Cancer Res, 53, pp.5853~5855 (1993)
25. Thibodeau SN, "Microsatellite instability in cancer of the proximal colon", Science, 260, pp.816~819 (1993)
26. Zhao P, "Mismatch repair deficiency", microsatellite instability-high as a predictor for anti-PD-1, J Hematol Oncol, pp.2019, 12[DOI]
27. Baudrin LG, "Molecular and computational methods for the detection of microsatellite instability in cancer", Front Oncol, 8, pp.621~ (2018)
28. Chen W, "Molecular genetics of microsatellite-unstable colorectal cancer for pathologists", Diagn Pathol, 12, pp.24~ (2017)
29. Richman S, "Deficient mismatch repair : read all about it(review)", Int J Oncol, 47, pp.1189~1202 (2015)
30. Salipante SJ, "Microsatellite instability detection by next generation sequencing", Clin Chem, 60, pp.1192~1199 (2014)
31. Niu B, "MSIsensor : microsatellite instability detection using paired tumor-normal sequence data", Bioinformatics, 30, pp.1015~1016 (2014)
32. Kautto EA, "Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS", Oncotarget, 8, pp.7452~7463 (2017)
33. Lu Y, "A novel approach for characterizing microsatellite instability in cancer cells", PLoS One, 8, pp.e63056~ (2013)
34. Dunstan RW, "The use of immunohistochemistry for biomarker assessment : can it compete with other technologies?", Toxicol Pathol, 39, pp.988~1002 (2011)
35. Jain KK, "The handbook of biomarkers" (2010), Springer
36. Coudray N, "Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning", Nat Med, 24, pp.1559~1567 (2018)
37. Khoury JD, "Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131clinical trial", Clin Cancer Res, 24, pp.521~531 (2018)
38. Kim KM, "Human epidermal growth factor receptor 2 testing in gastric cancer : recommendations of an Asia-Pacific task force", Asia Pac J Clin Oncol, 10, pp.297~307 (2014)
39. Garcia-Diaz A, "Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression", Cell Rep, 19, pp.1189~1201 (2017)
40. Zou W, "PD-L1(B7-H1)and PD-1 pathway blockade for cancer therapy : Mechanisms, response biomarkers, and combinations", Sci Transl Med, 8, pp.328rv4~ (2016)
41. Yang Q, "Multimodal detection of PD-L1 : reasonable biomarkers for immune checkpoint inhibitor", Am J Cancer Res, 8, pp.1689~1696 (2018)
42. Teng MW, "Classifying cancers based on T-cell infiltration and PD-L1", Cancer Res, 75, pp.2139~2145 (2015)
43. Taube JM, "Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape", Sci Transl Med, 4, pp.127ra37~ (2012)
44. Lee J, "Biomarkers for gastric cancer : molecular classification revisited", Precis Future Med, 1, pp.59~68 (2017)
45. Fridman WH, "The immune contexture in human tumours : impact on clinical outcome", Nat Rev Cancer, 12, pp.298~306 (2012)
46. Conroy JM, "Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors", J Immunother Cancer, 7, pp.18~ (2019)
47. Park C, "Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity", Oncoimmunology, 6, pp.e1356150~ (2017)

관련 논문AI추천